Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550968 | 0.82 | ALDH1A1 (0.52) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2747302 | 0.81 | ACLY (0.54) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2747923 | 0.81 | LMNA (0.65) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL5955438 | 0.77 | MAPT (0.72) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL3655682 | 0.72 | HSD17B2 (0.55) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL7124336 | 0.70 | MAPT (0.75) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6867994 | 0.69 | AKR1C3 (0.71) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL16295598 | 0.68 | POLB (0.52) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL13633887 | 0.68 | TDP1 (0.65) | MAPTUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL2434918 | 0.68 | MAPT (0.67) | MAPTUSP2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | MAPT 4049/4885USP2 2636/4885ALDH1A1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.